Cargando…

P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Welslau, M., Kubuschok, B., Topaly, J., Otremba, B., Wolff, T., Bryn, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430837/ http://dx.doi.org/10.1097/01.HS9.0000847548.21824.f5

Ejemplares similares

REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon(®)) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma
por: Welslau, Manfred, et al.
Publicado: (2023)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Study of the Stability of Sandoz Rituximab Biosimilar Rixathon(®)/Riximyo(®) When Subjected for up to 21 Days to Ambient Storage
por: Borišek, Roman, et al.
Publicado: (2022)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy
por: Xu, Xiao-xiao, et al.
Publicado: (2013)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting
por: Muntañola, Ana, et al.
Publicado: (2022)

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
por: Sekiguchi, Naohiro, et al.
Publicado: (2018)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

RTX-Toxins
por: Benz, Roland
Publicado: (2020)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

Bioavailability study of calcium sandoz-250 by atomic absorption spectroscopy in albino rats
por: Patel, Bimalkumar N., et al.
Publicado: (2014)

Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag)
por: Schapperer, Elisabeth, et al.
Publicado: (2015)

In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.
por: Brunton, V. G., et al.
Publicado: (1993)

Kingella kingae RtxA Cytotoxin in the Context of Other RTX Toxins
por: Filipi, Katerina, et al.
Publicado: (2022)

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
por: Olszewski, Adam J., et al.
Publicado: (2023)

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
por: Sekiguchi, Naohiro, et al.
Publicado: (2019)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment
por: Awasthi, Aradhana, et al.
Publicado: (2017)

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2021)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Publicado: (2022)

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
por: Wei, Xiaolei, et al.
Publicado: (2014)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

Modulation of Multidrug Resistance by SDZ PSC 833 in Leukemic and Solid‐tumor‐bearing Mouse Models
por: Watanabe, Toru, et al.
Publicado: (1996)

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
por: Gleeson, Mary, et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
por: Samineni, Divya, et al.
Publicado: (2021)

Rapid Purification of Endotoxin-Free RTX Toxins
por: Stanek, Ondrej, et al.
Publicado: (2019)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
por: Bai, J.-F., et al.
Publicado: (2022)

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
por: Martin, Peter, et al.
Publicado: (2023)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
por: Colombo, T., et al.
Publicado: (1996)

1171. Epidemiology of Old World Cutaneous Leishmaniasis among Members of the U.S. Military
por: Cebula, Brenan R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fpq3ppk5q88lep677p9t4jqb0l